Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535840) titled 'A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma' on April 10.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tongji Hospital
Condition:
HCC - Hepatocellular Carcinoma
TP53 Gene Mutation
Unresectable
Resistant Cancer
Intervention:
Drug: Firsekibart + Tislelizumab + Lenvatinib
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: May 2026
Target Sample Size: 25
To know more, vi...